drugset / Trial / NCT00396071

Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin

NCT00396071

Phase 3 Completed 22 enrolled Novartis Pharmaceuticals
RandomizedCrossoverDouble-blindTreatment

Summary

This mechanistic study will evaluate the effect of vildagliptin on glucose-stimulated insulin secretion to improve the incretin effect in patients with type 2 diabetes.

Timeline

Start
2006-10
Primary completion
2007-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Vildagliptin Other / unclassified 100 mg